drugset
drugset / Trial / NCT03825380

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

NCT03825380 ↗

Phase 3 Completed 485 enrolled Laboratoires Thea
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

Timeline

Start
2018-11-23
Primary completion
2021-02-03
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified — Topical

Indications

glaucoma ocular hypertension